Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12103976 Fc binding fragments comprising a CD137 antigen-binding site

Patent 12103976 was granted and assigned to invoX Pharma on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Mihriban Tuna0

Jose Munoz-Olaya0

Sarka Pechouckova0

Matthew Lakins0

Date of Patent

October 1, 2024

0

Patent Application Number

172597540

Date Filed

July 12, 2019

0

Patent Citations

US Patent 8383796 Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)

0

US Patent 8911732 Anti-mesothelin antibodies and immunoconjugates

0

US Patent 9567399 Antibodies and immunocytokines

0

US Patent 9617338 Antibodies and immunocytokines

0

US Patent 10090646 Spark plug

0

US Patent 10205305 Spark plug

0

US Patent 10233258 Bispecific binding proteins that bind CD40 and mesothelin

0

US Patent 10604576 Antibodies and immunocytokines

0

...

Patent Primary Examiner

0

Patent abstract

The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12103976 Fc binding fragments comprising a CD137 antigen-binding site

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool